Melanoma risk after ovarian stimulation for in vitro fertilization

Human Reproduction

Volumn 30, Issue 5, 2015, Pages 1216-1228

  Spaan, M ^a   Van Den Belt Dusebout, A W ^a   Schaapveld, M ^a   Mooij, T M ^a   Burger, C W ^b   Van Leeuwen, F E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

in vitro fertilization; infertility; melanoma; ovarian stimulation; parity

Indexed keywords

FOLLITROPIN; HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FEMALE SUBFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; GROUPS BY AGE; HUMAN; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; MELANOMA; MIDDLE AGED; NULLIPARA; OVARIAN STIMULATION; PARITY; RISK FACTOR; YOUNG ADULT; ADVERSE EFFECTS; COHORT ANALYSIS; NETHERLANDS; OVULATION INDUCTION; PROPORTIONAL HAZARDS MODEL; SKIN NEOPLASMS;

ADULT; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; HUMANS; MELANOMA; MIDDLE AGED; NETHERLANDS; OVULATION INDUCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84929752349     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev023     Document Type: Article

References (36)

1. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005;193:668-674.
2. Breslow NE, Day NE. Comparisons among exposure groups. Statistical Methods in Cancer Research, Volume II. Lyon: International Agency for Research on Cancer, 1987, 82-87.
3. Brinton LA, Melton LJ III, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol 1989;129:712-722.
4. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009;169:365-375.
5. De Boer EJ, Den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003;18: 1544-1552.
6. De Boer EJ, van Leeuwen FE, Den Tonkelaar I, Jansen CA, Braat DD, Burger CW. [Methods and results of in-vitro fertilisation in the Netherlands in the years 1983-1994]. Ned Tijdschr Geneeskd 2004; 148:1448-1455.
7. De Giorgi V, Mavilia C, Massi D, Gozzini A, Aragona P, Tanini A, Sestini S, Paglierani M, Boddi V, Brandi ML et al. Estrogen receptor expression in cutaneous melanoma: a real-Time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol 2009; 145:30-36.
8. Gandini S, Iodice S, Koomen E, Pietro AD, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-Analysis. Eur J Cancer 2011;47:2607-2617.
9. Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control 2008;19:759-765.
10. Hollestein LM, van den Akker SA, NijstenT, Karim-Kos HE, CoeberghJW, de Vries E. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslowthickness categories and rising mortality rates since 1989. Ann Oncol 2012;23:524-530.
11. IARC. Cancer incidence in five continents. Volume IX. IARC Sci Publ 2008; 160:1-837.
12. IKNL. Assocation of Comprensive Cancer Centers. Dutch Cancer figures. www.cijfersoverkanker.nl (18 December 2013, date last accessed).
13. Kaae J, Andersen A, Boyd HA, Wohlfahrt J, MelbyeM. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol 2007;165:1265-1270.
14. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-1389.
15. Klip H. Long-Term Health Effects of Subfertility Treatment. Amsterdam: Netherlands Cancer Institute, 2002.
16. Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol 2011;173:1192-1202.
17. Leslie KK, Espey E. Oral contraceptives and skin cancer: is there a link?. Am J Clin Dermatol 2005;6:349-355.
18. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20(Suppl 6):vi1-vi7.
19. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-1042.
20. Oliveria SA, Saraiya M, GellerAC, Heneghan MK, Jorgensen C. Sun exposure and risk of melanoma. Arch Dis Child 2006;91:131-138.
21. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995;5:123-127.
22. Silva Idos S, Wark PA, McCormackVA, Mayer D, Overton C, LittleV, Nieto J, Hardiman P, Davies M, MacLean AB. Ovulation-stimulation drugs and cancer risks: a long-Term follow-up of a British cohort. Br J Cancer 2009; 100:1824-1831.
23. Snell RS, Bischitz PG. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol 1960; 35:73-82.
24. Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. Association between in-vitro fertilization, birth and melanoma.Melanoma Res 2013;23:489-495.
25. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, Anderson ML, Zeitouni NC, Larson JC, Stefanick ML. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011;103:1469-1475.
26. Thornton MJ. The biological actions of estrogens on skin. Exp Dermatol 2002; 11:487-502.
27. Titus-Ernstoff L. An overview of the epidemiology of cutaneous melanoma. Clin Plast Surg 2000;27:305-316. vii.
28. Tomao F, Papa A, Lo Russo G, Zuber S, Spinelli GP, Rossi L, Caruso D, Prinzi N, Stati V, Benedetti Panici P et al. Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. Tumour Biol 2014;35:8415-8424.
29. Tucker MA. Melanoma epidemiology. Hematol Oncol Clin North Am 2009; 23:383-395. vii.
30. Van den Brandt PA, Goldbohm RA, t Veer P, Bode P, Dorant E, Hermus RJ, Sturmans F. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst 1993;85:224-229.
31. Van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a largeDutch cohort. HumReprod 2011;26:3456-3465.
32. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346:995-1000.
33. Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol 1987;5:1256-1261.
34. Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish womentreated for infertility.Hum Reprod 2012; 27:1149-1155.
35. Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. Melanoma Res 2001;11:535-541.
36. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res 2007;39:85-95.